1.20
price down icon4.00%   -0.05
after-market Dopo l'orario di chiusura: 1.16 -0.04 -3.33%
loading
Precedente Chiudi:
$1.25
Aprire:
$1.19
Volume 24 ore:
127.18K
Relative Volume:
0.95
Capitalizzazione di mercato:
$3.83M
Reddito:
$129.20K
Utile/perdita netta:
$-7.44M
Rapporto P/E:
-0.1072
EPS:
-11.19
Flusso di cassa netto:
$-8.62M
1 W Prestazione:
-10.45%
1M Prestazione:
-19.46%
6M Prestazione:
-74.47%
1 anno Prestazione:
-92.50%
Intervallo 1D:
Value
$1.10
$1.28
Intervallo di 1 settimana:
Value
$1.10
$1.70
Portata 52W:
Value
$1.10
$16.80

Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile

Name
Nome
Sonnet Biotherapeutics Holdings Inc
Name
Telefono
609-375-2227
Name
Indirizzo
100 OVERLOOK CENTER, PRINCETON, NJ
Name
Dipendente
0
Name
Cinguettio
@SonnetBio
Name
Prossima data di guadagno
2024-08-12
Name
Ultimi documenti SEC
Name
SONN's Discussions on Twitter

Confronta SONN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SONN
Sonnet Biotherapeutics Holdings Inc
1.20 3.83M 129.20K -7.44M -8.62M -11.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.56 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.78 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
550.00 33.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.95 30.15B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
220.54 25.69B 3.81B -644.79M -669.77M -6.24

Sonnet Biotherapeutics Holdings Inc Borsa (SONN) Ultime notizie

pulisher
10:33 AM

Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial - Yahoo Finance

10:33 AM
pulisher
Apr 06, 2025

Sonnet BioTherapeutics advances in cancer trial - Investing.com Australia

Apr 06, 2025
pulisher
Apr 04, 2025

Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo - TipRanks

Apr 04, 2025
pulisher
Apr 04, 2025

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - The Manila Times

Apr 04, 2025
pulisher
Apr 04, 2025

Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in - GlobeNewswire

Apr 04, 2025
pulisher
Apr 02, 2025

Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com Canada

Apr 02, 2025
pulisher
Apr 01, 2025

Sonnet Announces Release of Corporate Update Video - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics Announces New Interim CEO Appointment - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - NewsBreak: Local News & Alerts

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - citybiz

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Leadership Change at Sonnet BioTherapeutics: Founder Passes, New Executive Team Steps In - Stock Titan

Apr 01, 2025
pulisher
Mar 30, 2025

Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia

Mar 28, 2025
pulisher
Mar 27, 2025

Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire

Mar 27, 2025
pulisher
Mar 26, 2025

Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan

Mar 26, 2025
pulisher
Mar 21, 2025

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Major Patent Win: Sonnet's Revolutionary IL-18 Cancer Treatment Shows Superior Binding Properties - StockTitan

Mar 19, 2025
pulisher
Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

XRP Plunges as Recession Panic and Crypto Summit Fallout Slam Investors - The Globe and Mail

Mar 11, 2025
pulisher
Mar 07, 2025

Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga

Mar 07, 2025
pulisher
Mar 04, 2025

SONN stock touches 52-week low at $1.33 amid market challenges - Investing.com UK

Mar 04, 2025
pulisher
Feb 27, 2025

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Highlights Promising SON-1010 Data - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Innovative FHAB® Platform Data at 2025 AACR:IO Conference - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Compilation of Data - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can This Immunotherapy Beat Solid Tumors? Sonnet's SON-1010 Shows 48% Clinical Benefit - StockTitan

Feb 26, 2025
pulisher
Feb 21, 2025

Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships - The AM Reporter

Feb 21, 2025
pulisher
Feb 20, 2025

Sonnet BioTherapeutics advances novel ADC platform By Investing.com - Investing.com Australia

Feb 20, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics advances novel ADC platform - Investing.com

Feb 19, 2025
pulisher
Feb 19, 2025

SONN stock touches 52-week low at $1.38 amid market challenges - Investing.com India

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics Announces That Its Proprietary - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform - TipRanks

Feb 19, 2025

Sonnet Biotherapeutics Holdings Inc Azioni (SONN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.29
price down icon 0.48%
$68.09
price down icon 1.58%
$17.32
price down icon 0.23%
$31.03
price down icon 0.26%
$86.82
price down icon 1.40%
biotechnology ONC
$220.54
price down icon 7.53%
Capitalizzazione:     |  Volume (24 ore):